GSA Capital Partners LLP purchased a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 83,770 shares of the medical instruments supplier’s stock, valued at approximately $957,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Handelsbanken Fonder AB grew its holdings in shares of DENTSPLY SIRONA by 40.5% during the 4th quarter. Handelsbanken Fonder AB now owns 81,200 shares of the medical instruments supplier’s stock valued at $928,000 after purchasing an additional 23,400 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in shares of DENTSPLY SIRONA by 305.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 44,100 shares of the medical instruments supplier’s stock valued at $504,000 after purchasing an additional 33,212 shares during the last quarter. Gamco Investors INC. ET AL grew its holdings in shares of DENTSPLY SIRONA by 17.3% during the 4th quarter. Gamco Investors INC. ET AL now owns 186,300 shares of the medical instruments supplier’s stock valued at $2,129,000 after purchasing an additional 27,497 shares during the last quarter. Gabelli Funds LLC grew its holdings in shares of DENTSPLY SIRONA by 42.0% during the 4th quarter. Gabelli Funds LLC now owns 69,000 shares of the medical instruments supplier’s stock valued at $789,000 after purchasing an additional 20,392 shares during the last quarter. Finally, Dana Investment Advisors Inc. grew its holdings in shares of DENTSPLY SIRONA by 32.8% during the 4th quarter. Dana Investment Advisors Inc. now owns 371,741 shares of the medical instruments supplier’s stock valued at $4,249,000 after purchasing an additional 91,787 shares during the last quarter. 95.70% of the stock is owned by institutional investors.
DENTSPLY SIRONA Trading Up 2.8%
NASDAQ:XRAY opened at $10.21 on Friday. The firm’s fifty day moving average is $11.42 and its 200-day moving average is $11.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $17.09. The firm has a market cap of $2.05 billion, a P/E ratio of -3.24, a P/E/G ratio of 1.18 and a beta of 0.93.
Insiders Place Their Bets
In related news, Director James D. Forbes bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $124,800. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gregory T. Lucier bought 27,555 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were bought at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the transaction, the director directly owned 27,555 shares in the company, valued at $392,383.20. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 70,000 shares of company stock worth $956,437 in the last quarter. 0.50% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on XRAY shares. UBS Group reduced their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company boosted their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Barrington Research boosted their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Robert W. Baird boosted their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Citigroup initiated coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus price target of $13.82.
View Our Latest Stock Report on XRAY
DENTSPLY SIRONA Company Profile
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Read More
- Five stocks we like better than DENTSPLY SIRONA
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
